Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 84 of the 94 references it cites were found in a registry or an index, and 10 are not checked yet; 28 of the 138 sources its claims cite were checked for support.

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants

Open access

Published version of a preprint

Abstract

KRAS is the most frequently mutated oncogene, harboring mutations in approximately one in seven cancers. Allele-specific KRASG12C inhibitors are currently changing the treatment paradigm for patients with KRASG12C-mutated non–small cell lung cancer and colorectal cancer. The success of addressing a previously elusive KRAS allele has fueled drug discovery efforts for all KRAS mutants. Pan-KRAS drugs have the potential to address broad patient populations, including KRASG12D-, KRASG12V-, KRASG13D-, KRASG12R-, and KRASG12A-mutant or KRAS wild-type–amplified cancers, as well as cancers with acquired resistance to KRASG12C inhibitors. Here, we review actively pursued allele-specific and pan-KRAS inhibition strategies and their potential utility. Significance: Mutant-selective KRASG12C inhibitors target a fraction (approximately 13.6%) of all KRAS-driven cancers. A broad arsenal of KRAS drugs is needed to comprehensively conquer KRAS-driven cancers. Conceptually, we foresee two future classes of KRAS medicines: mutant-selective KRAS drugs targeting individual variant alleles and pan-KRAS therapeutics targeting a broad range of KRAS alterations.

Verified 2026-10-06 · 10 references not checked yet

Overview

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-21-1331

Cites

84 of 94 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

14 Valid · 4 Not valid · 66 Not checked · 37 Own results and interpretations

53 more claims · 2 with their cited sources checked

Create a free account to see all 121 claims and to verify the 110 references still open.

See all claims — free account
  • Probably not a substantial claim. 17
  • It may state two separate claims as one. 53
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 94 references

Research works printed but not linked: 2

  1. Kraut, 2021, Expanding the reach of precision oncology by drugging all KRAS mutants
  2. Scala, 2008, Generation and characterization of triple knockout mice for H, N and K-ras genes [dissertation

Cited by

See all 365

Metadata

Authors
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N.
Affiliations
  • Boehringer Ingelheim (Austria) (AT)
  • Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Kraut, Norbert
Venue
Cancer Discovery
Published
2022-01-19
Volume
12
Issue
4
Pages
924-937
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W4205933836
Cited by
336
References
94
Citations by year
2026: 59 · 2025: 86 · 2024: 80 · 2023: 78 · 2022: 33
FWCI
7.34
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (P30CA008748)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
KRAS mutation, pan-KRAS inhibitors, KRAS G12D, precision oncology, KRAS-driven cancers, non-small cell lung cancer, colorectal cancer
MeSH terms
Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Oncogenes, Proto-Oncogene Proteins p21(ras), Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. https://app.cochat.ai/papers/10.1158/2159-8290.cd-21-1331
The paper
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N. (2022). Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-21-1331

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.